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Abstract
Background: For decades, scientists have tried to understand the environmental factors involved in the
development of systemic lupus erythematosus (SLE), in which viral infections was included. Previous studies
have identified Epstein-Barr virus (EBV) to incite SLE. Human herpesvirus 8 (HHV-8), another member of the
gammaherpesvirus family, shares a lot in common with EBV. The characteristics of HHV-8 make it a well-suited
candidate to trigger SLE.
Results: In the present study, serum samples from patients (n = 108) with diagnosed SLE and matched controls
(n = 122) were collected, and the prevalence of HHV-8 was compared by a virus-specific nested PCR and a whole
virus enzyme-linked immunoassay (EIA). There was significant difference in the prevalence of HHV-8 DNA between
SLE patients and healthy controls (11 of 107 vs 1 of 122, p = 0.001); significant difference was also found in the
detection of HHV-8 antibodies (19 of 107 vs 2 of 122, p < 0.001).
We also detected the antibodies to Epstein-Barr virus viral capsid antigen (EBV-VCA) and Epstein-Barr nuclear
antigen-1 (EBNA-1). Both patients and controls showed high seroprevalence with no significant difference
(106 of 107 vs 119 of 122, p = 0.625).
Conclusion: Our finding indicated that there might be an association between HHV-8 and the development
of SLE.
Background
Systemic lupus erythematosus (SLE) is a disorder that
affects multiple organ systems. Patients with SLE display
abnormalities in immune system functions. For instance,
it causes enhanced B cell function and the production
of numerous autoantibodies. The etiology of SLE has
not been completely elucidated now, however, there is
striking evidence indicating that both genetic and envir-
onmental factors contribute to the development of SLE
[1]. In other words, genetic predispositions play its role
under the stimulation of environmental agents.
A number of viruses, including parvovirus B19 [2],
Epstein-Barr virus (EBV) [3,4], human papillomavirus
(HPV) [5,6], cytomegalovirus (CMV) [7], and some
endogenous retrovirus [8], have been implicated as pos-
sible environmental factors contributing to the onset
and/or exacerbation of SLE. One cogent example is EBV
infection, which has been identified as the environmen-
tal risk factor most closely associated with SLE [9].
Human herpesvirus 8 (HHV-8), or Kaposi’s sarcoma
(KS)-associated herpesvirus, have a well-established role
in the pathogenesis of KS. It belongs to the gammaher-
pesvirus subfamily and is closely related to Epstein-Barr
virus [10]. HHV-8 and EBV have many similarities: Both
of them are able to infect and build up latency in B lym-
phocytes. At the same time, they all have the abilities of
producing a number of proteins responsible for main-
taining viral episomes, promoting B-cell survival and
proliferation, inhibiting p53 and Rb, and most interest-
ing of all, encoding a large number of cellular homologs.
Two results can be reached due to the production of
cellular homologs. One is structural mimicry, as
Epstein-Barr virus nuclear antigen-1 (EBNA-1) mimics
human autoantigens Sm and Ro, which has been
regarded as one of the possible mechanisms contribut-
ing to the onset of autoimmunity [1]; another one is
functional mimicry, as HHV-8 expresses the homologs
of Bcl-2 to protect virus-infected cells from apoptosis,
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cellular counterparts to act [11].
Since the characteristics of HHV-8 itself and the cor-
relation between HHV-8 and EBV, we hypothesized that
the infection of HHV-8 was associated with SLE. From
patients with diagnosed SLE and healthy controls, serum
samples were collected to compare the prevalence of
HHV-8 in order to determine this association. Due to
the pathogenetic role of EBV in the development of
SLE, serologic tests were also performed to determine
the occurrence of it.
Methods
Study populations
All studies were carried out with the approval of the
local hospital ethical committee, patients (n = 108) with
SLE who fulfilled the 1997 revised American College of
Rheumatology criteria for SLE [12] and healthy controls
(n = 122) were enrolled in the study. The mean age and
female to male ratio were matched between patients
with SLE and healthy controls. (See Table 1 for demo-
graphics) All the participants enrolled in the study were
ethnic Chinese. Serum samples were obtained from
clinics at Xuanwu hospital, Beijing, China, between 2009
and 2010. In addition, those samples were stored at
-80°C within one hour of collection until tested.
Informed consent was obtained from each subject.
Virus-specific PCR detection
DNA was extracted from 0.5 ml of each serum sample
using the QIAamp Viral RNA Mini Kit (Qiagen), follow-
ing the instruction of the vendor. A fragment of b-actin
(304 bp) was amplified to confirm successful extraction
of DNA and no PCR inhibitors were present. One
patient was excluded in this study because of the failure
to amplify the fragment of b-actin.
DNA extracted from samples was examined for the
presence of a 233-bp-long fragment for HHV-8 (ORF26)
using a nested PCR protocol as previously described
[13]. The sensitivity of the nested PCR was determined
by series dilutions of the positive control, which has a
detection limit of 100 copies. For the first round PCR,
>1 0
3 target sequences could be detected (Figure 1).
Each first-round reaction was performed in a 25 μl
volume containing, 1.5 mM Mg
2+, 200 mM each dNTP,
0.4 μM each primer and 2 × Green Gotaq reaction buf-
fer (Promega) to which 100 ng DNA extract or control
was added. Second round reaction mixes were identical
to the first round and the templates were 1 μl products
from the first round reactions. Reaction conditions were
one cycle of 95°C for 2 min, thirty-five PCR cycles consist-
ing of denaturation at 95°C for 30 s, annealing at 50°C for
30 s and extension at 72°C for 30 s were run per round
with a 7 min final extension at 72°C for both first round
and nested PCR. PCR reactions containing all PCR
reagents without DNA template served as negative con-
trol. The 233-bp-long fragment for HHV-8 ORF26 was
amplified by means of a PCR-driven overlap extension
protocol and subsequently cloned into the pGEM-T vector
system kit (Promega) to serve as positive control. The first
and nested PCR products were analyzed in 1.5% TAE
agarose gels stained with ethidium bromide. For positive
samples, the nested PCR products was sequenced.
To minimize possible contaminations, Serum samples
from patients and healthy controls were randomly
selected and divided into several groups to extract DNA;
with each group contained sixteen samples, three sepa-
rate reactions of negative controls and one positive con-
trol were analyzed by PCR. DNA extraction, PCR and
gel electrophoresis were performed in separate rooms.
Positive samples were then validated by repeat testing.
Serological assays
To detect antibodies to HHV-8, serologic testing was
performed by a commercial ELISA (ABI) based on
whole virus lysate, according to the manufacturer’s
Table 1 Demographic data for study groups
Groups
Characteristics SLE Patients Normal Donors P value
Demographic Data
No. of participants 107 122
age (mean ± SD, yrs) 34.1 ± 12.1 33.5 ± 7.6 .72
Sex
Female (%) 93 (86.9) 111 (91.0) .33
Male (%) 14 (13.1) 11 (9.0)
Figure 1 Nested PCR sensitivity. Positive control was serially
diluted to be amplified by nested PCR. The detection limit of the
nested PCR assay used in this study was 100 copies. For the first
round PCR, > 10
3 target sequences could be detected.
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specificity of 99% [14].
The occurrence of infection with EBV was determined
by measuring IgG antibodies against EBV-VCA and
EBNA-1 (EUROIMMUN), following the manufacturer’s
instructions.
Statistical analysis
Data were expressed as the mean ± SD for normally dis-
tributed variables. Statistical analysis was performed
with SPSS v. 16.0. The association between HHV-8
infection and the occurrence of SLE was assessed using
the chi-square test; the association between EBV infec-
tion and the occurrence of SLE was assessed using the
Fisher’s Exact Test. The association Data with a P value
of less than 0.05 were considered significant.
Results
Detection of HHV-8 DNA
DNA isolated from sera was used as template to screen
for target sequence. Of the 107 patients with SLE, 11
(10.3%) were determined positive for HHV-8 ORF26;
whereas in healthy controls, 1/122 (0.8%) was positive.
The results between those two groups was statistically
different (p =0 . 0 0 1 ,b yc
2 test). All the repeat testing
for positive samples showed consistent results (Figure 2).
DNA sequence assay for positive PCR products showed
expected results for HHV-8 ORF26 sequences.
Serologic finding
Sera showed positive for IgG antibodies either against
EBV-VCA or against EBNA-1 were considered to be
EBV-positive. Both lupus patients and healthy controls
exhibited high incidence of infection with EBV (patients:
106/107 [99.1%]; controls: 119/122 [97.5%]), with no
significant difference (p = 0.625, by Fisher’s Exact Test)
was found.
Nineteen (17.8%) of 107 lupus patients and 2 (1.6%) of
122 matched controls were proven to be seropositive,
respectively. The results between those two groups was
statistically different (p < 0.001, by c
2 test). As shown in
table 2, of 19 those lupus patients showed seroreactivity,
ten were positive for both HHV-8 sequences and anti-
bodies; whereas one heathy control showed positive for
both HHV-8 sequences and antibodies of the two
healthy controls showed seroreactivity. All of the partici-
pents who were positive for HHV-8 DNA and HHV-8
antibodies showed positive for EBV antibodies.
Discussion
The results from PCR assays and serologic testing in our
study showed HHV-8 infection was more prevalent in
patients with SLE than in healthy controls. We found a
relatively low prevalence of HHV-8 in healthy controls,
which was similar with other studies on the epidemiol-
ogy of HHV-8 infection [15,16], suggesting that the pre-
valence of HHV-8 infection in China is low. Recently, a
survey conducted in the northwest of China revealed
that 20.4% of blood donors were seropositive for HHV-8
[17]. This observation suggested that the prevalence of
HHV-8 infection varies depending on different regions.
It is noteworthy to point out that the nested PCR is a
very sensitive tool with low detection limit, and serum
has been used to detect HHV-8 DNA [18-20]. However,
low detection rate of PCR detection has been observed
compared to that of serologic assays, which dues to the
low copy number and intermitent presence of HHV-8
DNA in serum [21-25].
An important finding of this study is the increased
prevalence of HHV-8 in patients with SLE, which indi-
cated that there might be an association between the
development of SLE and HHV-8. One acceptable expla-
nation may be the susceptibility of viral infection in
patients with SLE. As a disorder with impairment of the
immune system, SLE may lead to abnormalities of
humoral and cell mediated immune responses, cytokine
milieu and complement system. Furthermore, due to the
Figure 2 Positive samples for HHV8. A: Amplification of b-actin
(304 bp), B: the first round PCR (233 bp), C: the second round PCR
(195 bp). Lane N: negative control, Lane H: positive sample of
healthy controls, Lane 1-11: positive samples of patients with SLE,
Lane P: positive control.
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treatment, patients with SLE may be predisposed to
HHV-8 infection, thus resulting in a higher detection
rate of HHV-8 infection. This predisposition has been
observed in some transplant recipients and patients with
autoimmune disease or malignancy who have received
high dose of immunosuppressant agents [10], which
leads to iatrogenic KS.
On the other hand, relative to passive infection, is
there any possibility that HHV-8 actively involve in the
d e v e l o p m e n to fS L E ?T h ep a t h o g e n i cr o l eo fE B Vi n
SLE has been confirmed. As the gammaherpevirus
homolog for HHV-8, the virus can infect B cell latently,
providing the latent viral protein Epstein-Barr virus
nuclear antigen-1 (EBNA-1). EBNA-1 may molecularly
mimic the common human antigenic targets for the lupus
autoantigens. To date, only Sm and Ro have been identi-
fied to involve in molecular mimicry between EBV infec-
tion and SLE autoimmunity, which account for about 40%
of all SLE [9,26]. In our study, we screened the seropreva-
lence of EBV among the study subjects. High frequencies
of EBV infection were observed and no difference was
found between two groups. This finding was consistent
with the fact that EBV is a ubiquitous virus and indicated
that the infection of EBV is highly prevalent in China.
Also, we suspected that EBV might infect individuals long
before the onset of SLE, rather than secondary infection
resulting from impaired immune system or the application
of immunosuppressants.
Several mechanisms have been proposed by which
viruses trigger autoimmune diseases, including adjuvant
effects, molecular mimicry, bystander activation and epi-
tope spreading [1]. In these mechanisms: (a) viruses can
act as adjuvants to strengthen the function of antigen-
presenting cells (APCs) by pattern-recognition receptors
(PRRs), which recognize a large number of molecular
patterns present in viruses, resulting in the production
of inflammatory factors and in turn to tissue damage;
(b) viral antigens cross-reactive with self antigens allow
the activation of autoreactive T cells through molecular
mimicry; (c) self-antigens released from damaged tissue
were presented by activated APCs to autoreactive T
cells in the process of bystander activation; (d) addi-
tional autoreactive T cells responded for different por-
tion of the same protein or a different protein is
stimulated via epitope spreading. Considering the char-
acteristic of clinical and immunological heterogeneity,
and the large pool of autoantigens in patients with SLE,
it is possible that additional epitopes of different pro-
teins have the potential of molecular mimicry, which
means existing achievements are far from fully investi-
gated. Previous investigations have identified that HHV-
8 encodes a large number of cellular homologs. For
example, HHV-8 encodes viral interleukin-6 (vIL-6) in B
cells [27,28], intriguingly, resulting in B-cell survival and
proliferation. Therefore, HHV-8 could be regarded as a
superior candidate due to constant immune stimuli trig-
gered by the lifelong latency of itself.
Conclusions
In a relatively large population of Chinese patients with
SLE, we demonstrated that the prevalence of HHV-8 was
increased than that of in healthy controls. Our results
therefore implicate that there might be an association
between HHV-8 and the development of SLE. This
observation raises a series of important questions: Is
HHV-8 infection a critical factor in the pathogenesis of
SLE or a passenger virus? Whether HHV-8 can trigger
and/or exacerbate SLE as its gammaherpesvirus homolo-
gous EBV does? Is there other viruses play pathogenic
roles in the development of SLE? Considerable more
investigations, hopefully, will be done in this area.
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